In Vivo · 2020 · 12 citations · 29 references
MedicineOncologyPharmacologyApoptosisMolecular OncologyOncogenesBcl-2 Family ProteinsHematologic Malignancy PharmacotherapyHematologic Malignancy TherapyTyrosine Kinase InhibitorsAcute Lymphoblastic Leukemia TherapyAcute Lymphoblastic Leukemia TreatmentBcl-2 InhibitionBcl2 InhibitionBcr-abl InhibitorsChronic Myeloid Leukemia TherapyDisease Remission InductionTherapeutic Tyrosine Kinase Inhibitors
Background/Aim: Philadelphia-positive acute lymphoblastic leukemia (Ph + B-ALL) is caused by the malignant transformation of lymphoid cells induced by BCR-ABL1 constitutive catalytic activity. BCR-ABL1 tyrosine kinase inhibitors (TKIs) are effective against chronic myeloid leukemia (CML) cells, inducing durable hematological, cytogenetic and molecular responses. However, in Ph + B-ALL -as in CML progressing to blast crisis -TKIs fail to maintain disease remission. We, therefore, wanted to investigate if dual targeting of BCL-2 and BCR-ABL1 would be more effective in killing Ph + B-ALL cells. Materials and Methods: p210-B-ALL CD34-positive cells were used to evaluate the BCR-ABL expression and pharmacological targeting of BCL-2, by venetoclax, alone or in combination with BCR-ABL1 inhibition.
29
François Xavier Mahon, Michael W. Deininger, Beate Schultheis et al. · Blood · 2000 · 760 citations
The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1
Andrew A. Wylie, Joseph Schoepfer, Wolfgang Jahnke et al. · Nature · 2017 · 596 citations
Heather A. Bradeen, Christopher A. Eide, Thomas O’Hare et al. · Blood · 2006 · 401 citations · Full text
Philipp le Coutre, Oliver G. Ottmann, Francis J. Giles et al. · Blood · 2007 · 291 citations · Full text
Medicine, Oncology, Pharmacology +4